@article{FortmannDammannHumbergetal.2021,
  author    = {Fortmann, Ingmar and Dammann, Marie-Theres and Humberg, Alexander and Siller, Bastian and Stichtenoth, Guido and Engels, Geraldine and Marißen, Janina and Faust, Kirstin and Hanke, Kathrin and Goedicke-Fritz, Sybelle and Derouet, Christoph and Meyer, Sascha and Stutz, Regine and Kaiser, Elisabeth and Herting, Egbert and G{\"o}pel, Wolfgang and H{\"a}rtel, Christoph and Zemlin, Michael},
  title     = {Five year follow up of extremely low gestational age infants after timely or delayed administration of routine vaccinations},
  series = {Vaccines},
  volume    = {9},
  journal   = {Vaccines},
  number    = {5},
  issn      = {2076-393X},
  doi       = {10.3390/vaccines9050493},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-239592},
  year      = {2021},
  abstract  = {This study is aimed at detecting the rate of untimely immunization in a large cohort of extremely low gestational age neonates (ELGANs) of the German Neonatal Network (GNN) and at addressing risk factors for delayed vaccination and associated long-term consequences. We performed an observational study of the GNN between 1st January 2010 and 31st December 2019. The immunization status for the hexavalent and pneumococcal immunization was evaluated in n = 8401 preterm infants <29 weeks of gestation. Univariate analysis and logistic/linear regression models were used to identify risk factors for vaccination delay and outcomes at a 5-year follow-up. In our cohort n = 824 (9.8\%) ELGANs did not receive a timely first immunization with the hexavalent and pneumococcal vaccine. Risk factors for delayed vaccination were SGA status (18.1\% vs. 13.5\%; OR 1.3; 95\% CI: 1.1-1.7), impaired growth and surrogates for complicated clinical courses (i.e., need for inotropes, necrotizing enterocolitis). At 5 years of age, timely immunized children had a lower risk of bronchitis (episodes within last year: 27.3\% vs. 37.7\%; OR 0.60, 95\% CI: 0.42-0.86) but spirometry measures were unaffected. In conclusion, a significant proportion of ELGANs are untimely immunized, specifically those with increased vulnerability, even though they might particularly benefit from the immune-promoting effects of a timely vaccination.},
  language  = {en}
}
@article{FaustFreitagBarrientosetal.2021,
  author    = {Faust, Kirstin and Freitag, Nancy and Barrientos, Gabriela and Hartel, Christoph and Blois, Sandra M.},
  title     = {Galectin-Levels Are Elevated in Infants Born Preterm Due to Amniotic Infection and Rapidly Decline in the Neonatal Period},
  series = {Frontiers in Immunology},
  volume    = {11},
  journal   = {Frontiers in Immunology},
  issn      = {1664-3224},
  doi       = {10.3389/fimmu.2020.599104},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-230701},
  year      = {2021},
  abstract  = {Galectin (gal)-1, -3, and -9 are members of a family of glycan binding proteins that mediate complex interactions between decidual, inflammatory and trophoblast cells modulating several processes during gestation, control of the maternal immune system, and parturition. Their immunomodulatory role in preterm birth and postnatal expression in preterm infants is unknown. We performed a single center prospective study of 170 preterm infants with a gestational age below 35 weeks. Peripheral venous blood samples were collected during the neonatal period and galectin-1, -3, and -9 were determined by ELISA. We noted a strong decline of circulating gal-1 and -3 levels but not gal-9 from birth to day 7 of life. There was an inverse correlation of gal-1 and -3 levels at birth with gestational age. Gal-1 levels were remarkably increased in infants born to amniotic infection syndrome (AIS), which was also observed for gal-9 levels. Infants who developed early-onset sepsis had higher levels of gal-3 at day 1 as compared to unaffected infants. Our observational data imply that galectin-1, -3, and -9 levels are elevated in preterm infants born in an inflammatory milieu such as AIS or EOS. Future studies need to address whether galectins mediate inflammation-induced preterm birth and could therefore be a target for clinical trials.},
  language  = {en}
}